Search

Your search keyword '"Tomati V"' showing total 74 results

Search Constraints

Start Over You searched for: Author "Tomati V" Remove constraint Author: "Tomati V"
Sorry, I don't understand your search. ×
74 results on '"Tomati V"'

Search Results

Catalog

Books, media, physical & digital resources

3. WS05.02 CFTR rescue by lumacaftor (VX-809) induces an extensive reorganisation of mitochondria in the cystic fibrosis bronchial epithelium

4. Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes

8. Erratum: Corrigendum Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia (JCI Insight (2018) 3:3 (e98699) DOI: 10.1172/jci.insight.98699)

9. The role of functional studies in the diagnosis and treatment of Cystic Fibrosis: comparing the case of the G970D and G970R mutation

10. Genetic Inhibition of the Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated to F508del Cystic Fibrosis Mutation

11. Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation

12. A novel Bim-BH3-derived Bcl-XL inhibitor

15. Internalization via Antennapedia protein transduction domain of an scFv antibody toward c‐Myc protein

16. Inhibition of a protein‐protein interaction between INI1 and c‐Myc by small peptidomimetic molecules inspired by Helix‐1 of c‐Myc: identification of a new target of potential antineoplastic interest

17. Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein.

18. A novel Bim-BH3-derived Bcl-XL inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity

20. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment

21. Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel

22. Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity

23. Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators.

24. Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS).

25. Sources of biases in the in vitro testing of nanomaterials: the role of the biomolecular corona.

26. De novo variants in DENND5B cause a neurodevelopmental disorder.

27. SUMOylation Inhibition Enhances Protein Transcription under CMV Promoter: A Lesson from a Study with the F508del-CFTR Mutant.

28. Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5.

29. The combination elexacaftor/tezacaftor/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner.

30. Patient's dermal fibroblasts as disease markers for visceral myopathy.

31. Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background.

32. Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators.

33. Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes.

34. CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium.

35. Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors.

36. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.

37. The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs.

38. Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays.

39. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.

40. Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.

41. CFTR processing, trafficking and interactions.

42. Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel.

43. Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity.

44. SWATH label-free proteomics for cystic fibrosis research.

45. Two CFTR mutations within codon 970 differently impact on the chloride channel functionality.

47. The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR Through an Autophagy-Independent and USP13-Mediated Mechanism.

48. Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia.

49. Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.

50. High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel.